Copyright © 2005, European Society of Cardiology
A direct interaction between TGFβ activated kinase 1 and the TGFβ type II receptor: Implications for TGFβ signalling and cardiac hypertrophy
The Institute of Human Genetics, University of Newcastle Upon Tyne, Central Parkway, Newcastle Upon Tyne, NE1 3BZ, United Kingdom
* Corresponding author. Tel.: +44 191 241 8648; fax: +44 191 241 8666. Email address: Helen.Arthur{at}ncl.ac.uk
Objective: Transforming growth factor beta (TGFβ)-activated kinase 1 (TAK1) is a MAP kinase kinase kinase involved in numerous signalling pathways and is strongly implicated in cardiac hypertrophy and heart failure. TGFβ is also associated with hypertension and heart disease, and evidence suggests that TGFβ1 and TAK1 act together in a cardiac stress signalling pathway. Canonical TGFβ signalling is mediated through Smad transcription factors, but TGFβ can also rapidly activate TAK1. The activation of the Smad cascade is well characterised, but little is known about how TAK1 is activated in response to TGFβ, and no direct link between any MAPK kinase pathway and the TGFβ receptors has yet been established. Since TAK1 is activated by TGFβ within 1 min in cardiomyocytes, we hypothesised there might be a direct interaction between TAK1 and one of the TGFβ receptors.
Methods: We used a combination of in vitro binding assays and co-immunoprecipitation (IP) experiments to investigate whether TAK1 interacted with the type I (ALK1 or ALK5) or type II (TBRII) TGFβ receptors. Interactions between endogenous proteins were tested using mouse myoblast and rat cardiomyocyte cells.
Results: Immunoprecipitation and in vitro binding assays show that TAK1 binds directly to TBRII. Precipitation of endogenous TAK1 protein in rat cardiomyocytes shows that, in addition to a direct association with TBRII, it also interacts indirectly with ALK5.
Conclusions: We describe a novel and specific interaction between TAK1 and TBRII which, for the first time, directly links TAK1 to the TGFβ signalling cascade and potentially explains how TGFβ signalling in cardiomyocytes mediates a hypertrophic response.
KEYWORDS Angiotensin; Growth factors; Heart failure; Hypertrophy; MAP kinase
1 Authors contributed equally to this work.
Time for primary review 26 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. I. Kim, J. H. Kwak, H.-J. Na, J. K. Kim, Y. Ding, and M. E. Choi Transforming Growth Factor-{beta} (TGF-{beta}1) Activates TAK1 via TAB1-mediated Autophosphorylation, Independent of TGF-{beta} Receptor Kinase Activity in Mesangial Cells J. Biol. Chem., August 14, 2009; 284(33): 22285 - 22296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Carta, S. Smaldone, L. Zilberberg, D. Loch, H. C. Dietz, D. B. Rifkin, and F. Ramirez p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice J. Biol. Chem., February 27, 2009; 284(9): 5630 - 5636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Errami, C. L. Galindo, A. T. Tassa, J. M. DiMaio, J. A. Hill, and H. R. Garner Doxycycline Attenuates Isoproterenol- and Transverse Aortic Banding-Induced Cardiac Hypertrophy in Mice J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1196 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Barendrecht, A. C. M. Mulders, H. van der Poel, M. J. B. van den Hoff, M. Schmidt, and M. C. Michel Role of Transforming Growth Factor beta in Rat Bladder Smooth Muscle Cell Proliferation J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 117 - 122. [Abstract] [Full Text] [PDF]
|
|